Biomarkers of personalized peptide vaccination for metastatic upper tract urothelial carcinoma

• Project/Area Number: 15K10614
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Kurume University
• Principal Investigator: Suekane Shigetaka 久留米大学, 医学部, 准教授 (40235833)
• Co-Investigator(Kenkyū-buntansha): 野口 正典 久留米大学, 付置研究所, 教授 (10140691) ; 伊東 恭悟 久留米大学, 付置研究所, 教授 (50125499) ; 守屋 普久子 久留米大学, 医学部, 助教 (80449917)
• Co-Investigator(Renkei-kenkyūsha): MORIYA Fukuko 久留米大学, 医学部, 助教 (80449917)
• Research Collaborator: YAMADA Satoko
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: がんペプチドワクチン / 尿路上皮がん / バイオマーカー / サイトカイン / 生存率

Outline of Final Research Achievements

The aim of this study was to address the applicability of personalized peptide vaccination (PPV) to patients with metastatic upper tract urothelial cancer (mUTUC) who failed platinum-based chemotherapy. This study demonstrated that PPV induced substantial peptide-specific cytotoxic T lymphocyte responses without severe adverse events and has the potential to prolong survival for patients receiving PPV and salvage chemotherapy. Results of this study also suggest that the B cell activating factor (BAFF) level in pre-vaccination plasma might be potentially useful for selecting patients with mUTUC, who would benefit from PPV treatment as the precision medicine manner. The results suggest that PPV might be an important treatment option for patients with mUTUC after failure of platinum-based regimens.

Research Products

• [Journal Article] Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma. (2017)
  • Author(s): Suekane S, Ueda K, Nishihara K, Sasada T, Yamashita T, Koga N, Yutani S, Shichijo S, Itoh K, Igawa T, Noguchi M.
  • Journal Title: Cancer Sci. Volume: 108 Issue: 12 Pages: 2430-2437
  • DOI: 10.1111/cas.13404
  • Peer Reviewed / Open Access
• [Presentation] 転移性上部尿路上皮がん患者に対するペプチド特異CTL誘導のバイオマーカー (2017)
  • Author(s): 末金茂高
  • Organizer: 第55回日本癌治療学会総会
  • Place of Presentation: パシフィコ横浜
  • Year and Date: 2017-10-20
• [Presentation] Phase II study of personalized peptide vaccination for metastatic upper tract urothelial cancer patients refractory to the standard chemotherapy (2017)
  • Author(s): 末金茂高
  • Organizer: AUA2017
  • Place of Presentation: 米国ボストン
  • Year and Date: 2017-05-12
  • Int'l Joint Research
• [Presentation] 転移性上部尿路上皮がん患者に対するがんペプチドワクチン療法のバイオマーカー探索 (2017)
  • Author(s): 末金茂高
  • Organizer: 第105回日本泌尿器科学会総会
• [Presentation] 個別化がんペプチドワクチン療法 (2017)
  • Author(s): 末金茂高
  • Organizer: 第105回日本泌尿器科学会総会
  • Invited
• [Presentation] Phase Ⅱ study of personalized peptide vaccination for metastatic upper urinary tract urothelial cancer patients refractory to the standard chemotherapy (2017)
  • Author(s): 末金茂高
  • Organizer: AUA2017
  • Int'l Joint Research
• [Presentation] 転移性上部尿路上皮がん患者に対するぺプチド特異CTL誘導のバイオマーカー (2017)
  • Author(s): 末金茂高
  • Organizer: 第55回日本癌治療学会総会
• [Presentation] プラチナ系薬治療抵抗性転移性上部尿路上皮がん患者に対するがんペプチドワクチン療法 (2016)
  • Author(s): 末金茂高
  • Organizer: 日本癌治療学会
  • Place of Presentation: パシフィコ横浜
  • Year and Date: 2016-10-20
• [Presentation] 尿路上皮がん患者に対するがんペプチドワクチン療法の可能性 (2016)
  • Author(s): 末金茂高
  • Organizer: 日本泌尿器科学会東部総会
  • Place of Presentation: ホテル青森
  • Year and Date: 2016-10-07
• [Remarks] プラチナ製剤を含む化学療法耐性の転移性上部尿路上皮がんに対する個別化ペプチド
  • URL: http://www.med.kurume-u.ac.jp/med/cvc/activity.html